更新于：2024-12-14
Vecuronium Bromide
维库溴铵
更新于：2024-12-14
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C34H57BrN2O4 |
InChIKeyVEPSYABRBFXYIB-PWXDFCLTSA-M |
CAS号50700-72-6 |
关联
24
项与 维库溴铵 相关的临床试验Comparison of magnesium sulphate versus precurarisation dose of vecuronium in attenuating succinylcholine induced fasciculations and post operative myalgia. - NIL
Continuous Infusion Vs. Intermittent Goal Directed Administration of Vecuronium Bromide- A Double Blinded Randomised Controlled Study.
Assessing the intubating condition based on neuromuscular monitoring versus 3 minutes time after vecuronium induction A Randomised double blind study
100 项与 维库溴铵 相关的临床结果
登录后查看更多信息
100 项与 维库溴铵 相关的转化医学
登录后查看更多信息
100 项与 维库溴铵 相关的专利（医药）
登录后查看更多信息
3,616
项与 维库溴铵 相关的文献（医药）2024-11-01Anesthesia and analgesia
Effect of Changing Estimated Glomerular Filtration Rate Formula on Sugammadex Use and Pulmonary Complications for African American and non-African American Patients
Article
作者: Engoren, Milo ; Heung, Michael
BACKGROUND::
Sugammadex is associated with fewer postoperative pulmonary complications than is neostigmine reversal of neuromuscular blockade. However, the Food and Drug Administration-approved package insert states that its use is “not recommended” in severe renal impairment, separately defined as creatinine clearance <30 mL/min. Recently, the formula for estimating glomerular filtration rate (GFR) was updated to remove the race variable. Compared to the prior formula, the new consensus equation lowers the estimated GFR for African American patients and raises it for everyone else. We sought to determine how this change could differently impact the use of sugammadex, and thus the rate of pulmonary complications, for both African American and non-African American patients.
METHODS::
We used Monte Carlo simulation models to estimate the difference in pulmonary complications that would be suffered by patients when the change in creatine clearance calculated from the estimated GFR (using the old race-based and new race-neutral Chronic Kidney Disease Epidemiology Collaboration formulas) crossed the 30 mL/min threshold, which would require a change in sugammadex or neostigmine use.
RESULTS::
We found that 0.22% (95% confidence interval 0.14%–0.36%) of African American patients’ creatinine clearance would drop from above to below 30 mL/min making sugammadex not recommended and 0.19% (0.16%–0.22%) of non-African American patients would have creatinine clearance increase to >30 mL/min making sugammadex now recommended. Based on our model, we estimate that African American patients would suffer (count [95% confidence interval]) 3 [0.4–6] more pulmonary complications per 100,000 African American patients who received rocuronium or vecuronium through the change from sugammadex to neostigmine reversal to comply with labeling recommendations. Conversely, the same change in formulas would reduce the number of non-African American patients suffering pulmonary complications by 3 [2–4] per 100,000.
CONCLUSIONS::
The recent change in GFR formulas may potentially be associated with an increase in postoperative pulmonary complications in African American patients and a decrease in postoperative pulmonary complications in non-African American patients through GFR-driven changes in sugammadex use.
2024-11-01The Annals of pharmacotherapy
Sugammadex Use Outside of the Postoperative Setting
Article
作者: Gartner, Hayley T. ; Rech, Megan A.
Background::
Sugammadex rapidly reverses the nondepolarizing neuromuscular blocking agents (NMBAs) rocuronium and vecuronium. The role of sugammadex is not well-defined outside of the postoperative setting.
Objective::
This study aims to describe sugammadex use outside the postoperative setting for the reversal of nondepolarizing NMBAs.
Methods::
This was a single-center, retrospective cohort study conducted in patients who received sugammadex outside of the postoperative setting at an academic medical center between June 2016 and November 2022. The primary outcome was the effect of sugammadex use for rocuronium reversal, defined as any increase in train-of-four (TOF) after sugammadex administration and/or progress note documentation if TOF was unavailable. Secondary outcomes included adverse events and documentation of contraceptive counseling in patients taking hormonal contraceptives with child-bearing ability.
Results::
A total of 14 383 patients received sugammadex during the study period. Of those patients, 39 (0.3%) were outside of the postoperative setting for the reversal of rocuronium and included in the study. Twenty-nine (74%) patients had an increase in TOF after sugammadex administration and/or progress note documentation if TOF was unavailable. Ten (26%) patients lacked documentation regarding the effect of sugammadex. No adverse reactions were reported. Three (8%) patients included in the study were of child-bearing ability, and 1 of the 3 patients was counseled on using an alternative method of contraception following sugammadex administration.
Conclusion and Relevance::
There is a paucity of literature for the use of sugammadex outside of the postoperative setting. This study found that while the use of sugammadex was rare, overall, it was safe and well-tolerated.
2024-10-10JOURNAL OF MEDICINAL CHEMISTRY
Structure–Activity Relationship Studies Leading to the Discovery of Highly Water-Soluble and Biocompatible Acyclic Cucurbit[n]uril FY-3451 as a Universal Antagonist That Rapidly Reverses Neuromuscular Blocking Agents In Vivo
Article
作者: Wu, Yan ; Yang, Jingyu ; Zhang, Jiangshan ; Li, Qian ; Tian, Jia ; Ma, Da ; Liu, Yue-Yang ; Zhang, Dan-Wei ; Zhou, Wei ; Zong, Yang ; Feng, Ke ; Lei, Zhuo ; Qi, Qiao-Yan ; Lin, Furong ; Yu, Shang-Bo ; Zhuang, Sheng-Yi ; Li, Zhan-Ting
The development of a reversal agent that can rapidly reverse clinically used nondepolarizing neuromuscular blocking agents (NMBAs) has long been a challenge. Here, we report the synthesis of a series of highly water-soluble acyclic cucurbit[n]urils (acCBs). Systematic structure-activity relationship studies reveal that introducing two propylidene units on the peripheral benzene rings not only remarkably improves the activity of the corresponding derivative acCB6 (FY 3451) in reversing the neuromuscular block of rocuronium, cisatracurium, vecuronium, and pancuronium, the four clinically used NMBAs, through stable inclusion, but also allows for high water-solubility as well as a maximum tolerated dose (2000 mg/kg on rats). In vivo experiments with rats show that, at the identical dose of 25 mg/kg, for rocuronium, vecuronium, and pancuronium, acCB6 can achieve a recovery time shorter than that of sugammadex for rocuronium and, at the dose of 100 mg/kg, realize comparably rapid reversal for cisatracurium.
100 项与 维库溴铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1999-01-01 | |
| 麻醉 | 美国 | 1984-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 86 | opioids (Observational) | 簾顧壓獵憲網繭鬱夢糧(壓艱壓構淵鬱築廠齋鬱) = 鏇廠鹹膚鏇淵構糧鹽齋 蓋壓鏇衊範餘夢艱齋醖 (鹹襯繭衊鏇齋憲襯壓繭, 壓廠膚遞壓齋範鑰築醖 ~ 艱憲淵艱鬱衊膚蓋襯構) 更多 | - | 2020-10-12 | ||
regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+rocuronium+Celecoxib+vecuronium+Gabapentin (Non-Opioid Intervention) | 簾顧壓獵憲網繭鬱夢糧(壓艱壓構淵鬱築廠齋鬱) = 繭窪蓋壓鬱壓鏇鬱簾積 蓋壓鏇衊範餘夢艱齋醖 (鹹襯繭衊鏇齋憲襯壓繭, 鹽膚襯範膚遞襯積選壓 ~ 艱蓋築選築淵廠餘襯艱) 更多 | ||||||
临床4期 | 344 | (Sugammadex 2 mg/kg) | 蓋簾獵遞顧願構襯淵淵(蓋膚築艱膚鹹膚齋襯廠) = 醖鬱餘範夢壓鹹遞廠鹽 範鹽積構築鑰壓網製鏇 (獵襯選鬱壓築遞窪築製, 襯衊淵壓齋衊壓簾廠繭 ~ 選壓願顧餘構齋鹹膚積) 更多 | - | 2020-10-08 | ||
(Sugammadex 4 mg/kg) | 蓋簾獵遞顧願構襯淵淵(蓋膚築艱膚鹹膚齋襯廠) = 製繭遞鹹壓觸襯膚膚鬱 範鹽積構築鑰壓網製鏇 (獵襯選鬱壓築遞窪築製, 襯淵鏇廠築願鬱網獵範 ~ 觸製鬱鑰淵獵艱壓壓築) 更多 | ||||||
临床4期 | - | 207 | (Sugammadex 2 mg/kg ABW) | 顧鏇齋蓋鏇夢壓選醖顧(蓋繭顧遞壓簾鹹窪簾範) = 餘鹽鏇鏇鬱觸襯壓繭鑰 憲鹽齋艱窪簾繭艱遞餘 (餘願廠衊衊壓夢壓艱壓, 艱蓋製衊醖鹽餘鏇選夢 ~ 積繭齋鏇蓋鹹衊積襯鏇) 更多 | - | 2019-12-23 | |
(Sugammadex 4 mg/kg ABW) | 顧鏇齋蓋鏇夢壓選醖顧(蓋繭顧遞壓簾鹹窪簾範) = 窪獵鏇顧製艱窪築獵獵 憲鹽齋艱窪簾繭艱遞餘 (餘願廠衊衊壓夢壓艱壓, 構壓醖願憲製憲餘選製 ~ 衊鹹鏇範醖鹽繭繭齋築) 更多 | ||||||
临床4期 | 116 | 顧艱範築鑰壓淵鹹餘觸(鑰顧衊糧衊齋鹹膚簾積) = 顧築選鏇憲築製鏇網構 憲壓廠鏇窪醖積鏇窪顧 (鏇網窪憲網築衊糧壓觸, 繭壓鹹製選鬱窪鏇鹹憲 ~ 顧觸憲襯遞齋夢築鑰衊) 更多 | - | 2019-09-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用